Stephen Garbacz
Corporate Officer/Principal chez Tessera Therapeutics, Inc.
Postes actifs de Stephen Garbacz
Sociétés | Poste | Début | Fin |
---|---|---|---|
Tessera Therapeutics, Inc.
Tessera Therapeutics, Inc. BiotechnologyHealth Technology Tessera Therapeutics, Inc. engages in science company. It offers scientists and doctors the ability to write and rewrite small and large therapeutic messages into the genome, thereby curing diseases at their source. The company is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/05/2021 | - |
Historique de carrière de Stephen Garbacz
Anciens postes connus de Stephen Garbacz
Sociétés | Poste | Début | Fin |
---|---|---|---|
ANIKA THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 06/05/2019 | 01/05/2021 |
SPERO THERAPEUTICS, INC. | Directeur des opérations | 01/01/2015 | - |
Corporate Officer/Principal | 01/01/2015 | - | |
EPIZYME, INC. | Comptroller/Controller/Auditor | 01/10/2014 | 09/02/2015 |
Directeur Financier/CFO | 01/08/2012 | - |
Formation de Stephen Garbacz
The Leonard N Stern School of Business | Masters Business Admin |
George Mason University | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 7 |
Opérationnelle
Comptroller/Controller/Auditor | 2 |
Corporate Officer/Principal | 2 |
Director of Finance/CFO | 1 |
Sectorielle
Health Technology | 5 |
Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 2 |
---|---|
SPERO THERAPEUTICS, INC. | Health Technology |
ANIKA THERAPEUTICS, INC. | Health Technology |
Entreprise privées | 2 |
---|---|
Epizyme, Inc.
Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
Tessera Therapeutics, Inc.
Tessera Therapeutics, Inc. BiotechnologyHealth Technology Tessera Therapeutics, Inc. engages in science company. It offers scientists and doctors the ability to write and rewrite small and large therapeutic messages into the genome, thereby curing diseases at their source. The company is headquartered in Cambridge, MA. | Health Technology |
- Bourse
- Insiders
- Stephen Garbacz
- Expérience